These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 30016231)

  • 21. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
    Aktaş Z; Kayacan C; Oncul O
    Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis.
    Kuti JL; Pettit RS; Neu N; Cies JJ; Lapin C; Muhlebach MS; Novak KJ; Nguyen ST; Saiman L; Nicolau DP
    Diagn Microbiol Infect Dis; 2015 Sep; 83(1):53-5. PubMed ID: 26003469
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Crémet L; Joffraud L; Eschapasse E; Bihouée T; Tissot A; Gibaud S; Persyn E
    Microb Drug Resist; 2022 Aug; 28(8):877-881. PubMed ID: 35763306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of seven β-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients.
    Massip C; Mathieu C; Gaudru C; Miaut V; Floch P; Oswald E; Segonds C; Guet-Revillet H
    J Antimicrob Chemother; 2019 Feb; 74(2):525-528. PubMed ID: 30312409
    [No Abstract]   [Full Text] [Related]  

  • 25. Increasing Incidence of Multidrug Resistance Among Cystic Fibrosis Respiratory Bacterial Isolates.
    Rutter WC; Burgess DR; Burgess DS
    Microb Drug Resist; 2017 Jan; 23(1):51-55. PubMed ID: 27326758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. "Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant
    Zeiser ET; Becka SA; Wilson BM; Barnes MD; LiPuma JJ; Papp-Wallace KM
    J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Seasonality of acquisition of respiratory bacterial pathogens in young children with cystic fibrosis.
    Psoter KJ; De Roos AJ; Wakefield J; Mayer JD; Rosenfeld M
    BMC Infect Dis; 2017 Jun; 17(1):411. PubMed ID: 28599639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.
    Scribner RK; Marks MI; Weber AH; Tarpay MM; Welch DF
    Antimicrob Agents Chemother; 1982 Jun; 21(6):939-43. PubMed ID: 6810757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stenotrophomonas maltophilia susceptibility to ceftazidime-avibactam combination versus ceftazidime alone.
    Moriceau C; Eveillard M; Lemarié C; Chenouard R; Pailhoriès H; Kempf M
    Med Mal Infect; 2020 May; 50(3):305-307. PubMed ID: 32014291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population Structure, Molecular Epidemiology, and β-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United States.
    Mojica MF; Rutter JD; Taracila M; Abriata LA; Fouts DE; Papp-Wallace KM; Walsh TJ; LiPuma JJ; Vila AJ; Bonomo RA
    mBio; 2019 Jul; 10(4):. PubMed ID: 31266860
    [No Abstract]   [Full Text] [Related]  

  • 31. Mutation-Driven Evolution of Pseudomonas aeruginosa in the Presence of either Ceftazidime or Ceftazidime-Avibactam.
    Sanz-García F; Hernando-Amado S; Martínez JL
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30082283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The indirect pathogenicity of Stenotrophomonas maltophilia.
    Kataoka D; Fujiwara H; Kawakami T; Tanaka Y; Tanimoto A; Ikawa S; Tanaka Y
    Int J Antimicrob Agents; 2003 Dec; 22(6):601-6. PubMed ID: 14659658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013.
    Sader HS; Castanheira M; Mendes RE; Flamm RK; Farrell DJ; Jones RN
    Antimicrob Agents Chemother; 2015; 59(6):3656-9. PubMed ID: 25845861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Denitrification by cystic fibrosis pathogens - Stenotrophomonas maltophilia is dormant in sputum.
    Kolpen M; Kragh KN; Bjarnsholt T; Line L; Hansen CR; Dalbøge CS; Hansen N; Kühl M; Høiby N; Jensen PØ
    Int J Med Microbiol; 2015 Jan; 305(1):1-10. PubMed ID: 25441256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural/mechanistic insights into the efficacy of nonclassical β-lactamase inhibitors against extensively drug resistant Stenotrophomonas maltophilia clinical isolates.
    Calvopiña K; Hinchliffe P; Brem J; Heesom KJ; Johnson S; Cain R; Lohans CT; Fishwick CWG; Schofield CJ; Spencer J; Avison MB
    Mol Microbiol; 2017 Nov; 106(3):492-504. PubMed ID: 28876489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.
    Yoshizumi A; Ishii Y; Aoki K; Testa R; Nichols WW; Tateda K
    J Infect Chemother; 2015 Feb; 21(2):148-51. PubMed ID: 25444674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Shared genotypes of Achromobacter xylosoxidans strains isolated from patients at a cystic fibrosis rehabilitation center.
    Van Daele S; Verhelst R; Claeys G; Verschraegen G; Franckx H; Van Simaey L; de Ganck C; De Baets F; Vaneechoutte M
    J Clin Microbiol; 2005 Jun; 43(6):2998-3002. PubMed ID: 15956444
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Menetrey Q; Sorlin P; Jumas-Bilak E; Chiron R; Dupont C; Marchandin H
    Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33919046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with noncystic fibrosis isolates.
    Cantón R; Valdezate S; Vindel A; Sánchez Del Saz B; Maíz L; Baquero F
    Pediatr Pulmonol; 2003 Feb; 35(2):99-107. PubMed ID: 12526070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.
    Papp-Wallace KM; Bajaksouzian S; Abdelhamed AM; Foster AN; Winkler ML; Gatta JA; Nichols WW; Testa R; Bonomo RA; Jacobs MR
    Diagn Microbiol Infect Dis; 2015 May; 82(1):65-9. PubMed ID: 25737290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.